Abstract:Background: Clinical studies have shown that about two-thirds of patients with chronic pain suffer from short-term memory (STM) deficits and an effective drug for treatment of the neurological disorder is lacking at present.Objective: We tested whether chronic oral application of magnesium L-threonate (MgT), which has been shown to improve memory in normal and aging animals by elevating Mg2+ in the brain, could prevent or restore the STM deficits induced by spared nerve injury (SNI), an animal model of chronic neuropathic pain. The mechanisms underlying the effect of MgT on STM deficits were also investigated.Study Design: The experiments were conducted in a random and double-blind fashion in adult male rats. MgT was administrated via drinking water at a dose of 609 mg/kg/d for 2 weeks, starting either one week before SNI (preventative group) or one week after SNI (therapeutic group), and water without the drug served as control.Methods: STM was accessed with a novel object recognition test (NORT), followed by recording of long-term potentiation (LTP) in the hippocampus in vivo and the measurement of the expression of tumor necrosis factor-alpha (TNF-alpha) with Western Blot or Immunohistochemistrical staining. alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) and N-methyl-D-aspartic acid (NMDA) receptor (NMDAR) currents were recorded with patch clamp in CA1 neurons in acute and cultured hippocampal slices.Result: We found that chronic oral application of MgT was able to prevent and restore the deficits of STM and of LTP at CA3-CA1 synapses in the hippocampus induced by SNI. Furthermore, both preventative and therapeutic chronic oral application of MgT blocked the up-regulation of TNF-alpha in the hippocampus, which has been previously shown to be critical for memory deficits. SNI reduced NMDAR current and the effect was dramatically attenuated by elevating extracellular Mg2+ concentration ([Mg2+](o)). In cultured hippocampal slices, chronic application of recombinant rat TNF-alpha (rrTNF-alpha) for 3 days reduced NMDAR current in a concentration-dependent manner and the effect was again blocked by elevating [Mg2+](o).Limitations: We showed that oral application of MgT inhibited the over-expression of TNF-alpha and rescued the dysfunction of the NMDAR, but the causal relationship between them remains elusive.Conclusions: Our data suggested that oral application of MgT was able to prevent and restore the STM deficits in an animal model of chronic neuropathic pain by reversing the dysfunction of the NMDAR, and normalization of TNF-alpha expression may play a role in the effect. Oral application of MgT may be a simple and potent means for handling this form of memory deficit.

Elevation of Brain Magnesium Prevents and Reverses Cognitive Deficits and Synaptic Loss in Alzheimer's Disease Mouse Model (Retraction of vol 33, pg 8423, 2013)

Prevention of Cognitive Deficits in Alzheimer’s Mouse Model by Elevating Brain Magnesium

By suppressing the expression of anterior pharynx-defective-1α and -1β and inhibiting the aggregation of β-amyloid protein, magnesium ions inhibit the cognitive decline of amyloid precursor protein/presenilin 1 transgenic mice

Magnesium boosts the memory restorative effect of environmental enrichment in Alzheimer's disease mice

Magnesium ion influx reduces neuroinflammation in Aβ precursor protein/Presenilin 1 transgenic mice by suppressing the expression of interleukin-1β

Retracted: 1h-Mrs Can Monitor Metabolites Changes Of Lateral Intraventricular Bdnf Infusion Into A Mouse Model Of Alzheimer'S Disease In Vivo(Retracted Article. See Vol. 254, Pg. 477, 2013)

Enhancement of learning and memory by elevating brain magnesium.

Magnesium modulates amyloid-beta protein precursor trafficking and processing.

Retracted: 1H-MRS Can Monitor Metabolites Changes of Lateral Intraventricular BDNF Infusion into a Mouse Model of Alzheimer’s Disease in Vivo [neuroscience 245 (2013) 40–49]

Magnesium-L-threonate treats Alzheimer's disease by modulating the microbiota-gut-brain axis

Magnesium-L-threonate treats Alzheimer’s disease by modulating the microbiota-gut-brain axis

Magnesium Reduces Blood-Brain Barrier Permeability and Regulates Amyloid-β Transcytosis

Magnesium Ions Inhibit the Expression of Tumor Necrosis Factor Α and the Activity of Γ-Secretase in a Β-Amyloid Protein-Dependent Mechanism in APP/PS1 Transgenic Mice.

Effects of elevation of brain magnesium on fear conditioning, fear extinction, and synaptic plasticity in the infralimbic prefrontal cortex and lateral amygdala

Regulation of structural and functional synapse density by L-threonate through modulation of intraneuronal magnesium concentration

Memory impairments in Tg19959 and APP/PS1 AD model mice are alleviated by eEF2K inhibitor A‐484954

Targeting the NMDA receptor subunit NR2B for treating or preventing age-related memory decline

Memantine Improves Cognitive Function and Alters Hippocampal and Cortical Proteome in Triple Transgenic Mouse Model of Alzheimer's Disease

Inhibition of 2-Arachidonoylglycerol Metabolism Alleviates Neuropathology and Improves Cognitive Function in a Tau Mouse Model of Alzheimer’s Disease

Magnesium L-threonate Prevents and Restores Memory Deficits Associated with Neuropathic Pain by Inhibition of TNF-α

Gamma Rhythm Low Field Magnetic Stimulation Alleviates Neuropathologic Changes and Rescues Memory and Cognitive Impairments in a Mouse Model of Alzheimer's Disease.